Grail, the San Francisco company that has raised $1.6 billion to develop a blood test to detect cancer, announced Thursday that it had appointed Hans Bishop, previously the CEO of Juno Therapeutics, as its new chief executive.
Bishop, who led Juno until it was sold to Celgene for $9 billion in March 2018, will be the third chief executive Grail has had since it was founded in 2015. He will replace Jennifer Cook, a former Roche executive; Grail said Cook was leaving the CEO job for family health reasons.
The company also said its chief financial officer, Renée Galá, has decided to step down, and Joshua Ofman, formerly a senior vice president at Amgen, would join as chief of corporate strategy.
About the Author Reprints
